Bruno Zwingenberger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bruno Zwingenberger has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Corina Vater
University Center of Orthopaedic, Trauma and Plastic Surgery, University Hospital Carl Gustav Carus and Faculty of Medicine at TUD Dresden University of Technology, 01307, Dresden, Germany; Center for Translational Bone, Joint and Soft Tissue Research, University Hospital Carl Gustav Carus and Faculty of Medicine at TUD Dresden University of Technology, 01307, Dresden, Germany
1 shared publication - Dilbar Aibibu
Institute of Textile Machinery and High Performance Material Technology, Technische Universität Dresden Dresden Germany
1 shared publication - Elisabeth Mehnert
University Center of Orthopedic, Trauma and Plastic Surgery, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
1 shared publication - Julia Bolte
University Center of Orthopedic, Trauma and Plastic Surgery, University Hospital Carl Gustav Carus at TU Dresden, 01307 Dresden, Germany
1 shared publication - Roland L. Bell
Department of Trauma-, Reconstructive- and Hand-Surgery, Municipal Hospital of the City of Dresden, 01067 Dresden, Germany
1 shared publication - Ronny Brünler
Institute of Textile Machinery and High Performance Material Technology (ITM), Technische Universität Dresden, Hohe Str. 6, 01069 Dresden, Germany
1 shared publication
Latest Publications
- Open Access
- 14 August 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (8) , 1015
Treatment of Critical-Size Femoral Bone Defects with Chitosan Scaffolds Produced by a Novel Process from Textile Engineering
The purpose of this study was to investigate, in vitro and in vivo, the suitability of chitosan (CHS) scaffolds produced by the net-shape-nonwoven (NSN) technology, for use as bone graft substitutes in a critical-size femoral bone defect in rats. For in vitro investigations, scaffolds made of CHS, mineralized collagen (MCM), or human cancellous bone allograft (CBA) were seeded with human telomerase-immortalized mesenchymal stromal cells (hTERT-MSC), incubated for 14 days, and thereafter evaluated for proliferation and osteogenic differentiation. In vivo, CHS, MCM and CBA scaffolds were implanted into 5 mm critical-size femoral bone defects in rats. After 12 weeks, the volume of newly formed bone was determined by microcomputed tomography (µCT), while the degree of defect healing, as well as vascularization and the number of osteoblasts and osteoclasts, was evaluated histologically. In vitro, CHS scaffolds showed significantly higher osteogenic properties, whereas treatment with CHS, in vivo, led to a lower grade of bone-healing compared to CBA and MCM. While chitosan offers a completely new field of scaffold production by fibers, these scaffolds will have to be improved in the future, regarding mechanical stability and osteoconductivity.
- 14 August 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (8) , 1015
Open AccessTreatment of Critical-Size Femoral Bone Defects with Chitosan Scaffolds Produced by a Novel Process from Textile Engineering
The purpose of this study was to investigate, in vitro and in vivo, the suitability of chitosan (CHS) scaffolds produced by the net-shape-nonwoven (NSN) technology, for use as bone graft substitutes in a critical-size femoral bone defect in rats. For in vitro investigations, scaffolds made of CHS, mineralized collagen (MCM), or human cancellous bone allograft (CBA) were seeded with human telomerase-immortalized mesenchymal stromal cells (hTERT-MSC), incubated for 14 days, and thereafter evaluated for proliferation and osteogenic differentiation. In vivo, CHS, MCM and CBA scaffolds were implanted into 5 mm critical-size femoral bone defects in rats. After 12 weeks, the volume of newly formed bone was determined by microcomputed tomography (µCT), while the degree of defect healing, as well as vascularization and the number of osteoblasts and osteoclasts, was evaluated histologically. In vitro, CHS scaffolds showed significantly higher osteogenic properties, whereas treatment with CHS, in vivo, led to a lower grade of bone-healing compared to CBA and MCM. While chitosan offers a completely new field of scaffold production by fibers, these scaffolds will have to be improved in the future, regarding mechanical stability and osteoconductivity.